Distinguishing benign from pathogenic duplications involving GPR101 and VGLL1 -adjacent enhancers in the clinical setting with the bioinformatic tool POSTRE
Authors:
- Giampaolo TrivellinGTGiampaolo Trivellin
- Víctor Sánchez-GayaVSVíctor Sánchez-Gaya
- Alexia GrassoAGAlexia Grasso
- Magdalena PasińskaMPMagdalena Pasińska
- Constantine A. StratakisConstantine A. Stratakis
- Di MilnesDMDi Milnes
- Edwin P. KirkEKEdwin P. Kirk
- Albert BeckersABAlbert Beckers
- Andrea G. LaniaAndrea G. Lania
- Patrick PétrossiansPPPatrick Pétrossians
- Alvaro Rada-IglesiasARAlvaro Rada-Iglesias
- Martin FrankeMFMartin Franke
Preprint
Abstract
Background: Structural variants (SVs) that disrupt topologically associating domains (TADs) can cause disease by rewiring enhancer-promoter interactions. Duplications involving GPR101 are known to cause X-linked acrogigantism (X-LAG) by enabling aberrant expression of GPR101 through hijacking of enhancers at VGLL1 . However, not all GPR101 -containing duplications are pathogenic, presenting a diagnostic challenge, especially in the prenatal setting. Methods: We evaluated POSTRE, a tool designed to predict the regulatory impact of SVs, to distinguish pathogenic from benign GPR101 duplications. We analyzed six non-pathogenic duplications, and 27 known X-LAG associated pathogenic duplications. Tissue-specific enhancer maps built using H3K27ac ChIP-seq and ATAC-seq data as well as gene expression data derived from human anterior pituitary samples were integrated into POSTRE to enable predictions in a X-LAG relevant tissue context. Results: POSTRE correctly classified all 33 duplications as benign or pathogenic. In addition, one X-LAG case with mild clinical features (e.g., severe GH hypersecretion in the absence of pituitary tumorigenesis) was found to include only 2/5 VGLL1 enhancers (also predicted to be the weakest enhancers), whereas all 26 typical X-LAG cases had 24 enhancers duplicated. This suggests that milder enhancer hijacking at VGLL1 could explain the different clinical features of X-LAG in this individual. Conclusions: These findings support the utility of POSTRE to support diagnostic pipelines when interpreting SVs affecting chromatin architecture in pituitary disease. By accurately modelling enhancer adoption in a cell type-specific context, POSTRE could help to reduce uncertainty in genetic counselling and offers a rapid alternative to performing chromatin conformation capture experiments.Keywords
This publication has 41 references indexed in Scilit:
- Unraveling the three-dimensional (3D) genome architecture in Neurodevelopmental Disorders (NDDs)neurogenetics, 2024
- Structural Variants at the LMNB1 Locus: Deciphering Pathomechanisms in Autosomal Dominant Adult‐Onset Demyelinating LeukodystrophyAnnals of Neurology, 2024
- Super-enhancers include classical enhancers and facilitators to fully activate gene expressionCell, 2023
- Duplications disrupt chromatin architecture and rewire GPR101-enhancer communication in X-linked acrogigantismThe American Journal of Human Genetics, 2022
- Genetics, clinical features and outcomes of non-syndromic pituitary gigantism: experience of a single center from Sao Paulo, BrazilPituitary, 2020
- Structural Variants Create New Topological-Associated Domains and Ectopic Retinal Enhancer-Gene Contact in Dominant Retinitis PigmentosaThe American Journal of Human Genetics, 2020
- Enhancer and super‐enhancer: Positive regulators in gene transcriptionAnimal Models and Experimental Medicine, 2018
- An orphan G-protein-coupled receptor causes human gigantism and/or acromegaly: Molecular biology and clinical correlationsBest Practice & Research Clinical Endocrinology & Metabolism, 2018
- Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndromeEndocrine, 2015
- Segmental folding of chromosomes: A basis for structural and regulatory chromosomal neighborhoods?BioEssays, 2013